Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins
- Autores
- Lucero, Diego Martín; Miksztowicz, Verónica Julieta; Gualano, Gisela; Longo, Cristina; Landeira, Graciela; Álvarez, Estela; Zago, Valeria; Brites, Fernando Daniel; Berg, Gabriela Alicia; Fassio, Eduardo; Schreier, Laura Ester
- Año de publicación
- 2017
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Background We evaluated possible changes in VLDLcharacteristics, and metabolic related factors, in MetS-associated NAFLD and accompanying liver fibrosis. Methods We studied 36 MetS patients with biopsy-proven NAFLD (MetS + NAFLD) and 24 MetS without ultrasound NAFLD evidence. Further, MetS + NAFLD was sub-divided according to fibrosis stage into, non-to-moderate (F0–F2, n = 27) and severe (F3–F4, n = 9) fibrosis. We measured: lipid profile, VLDL composition and size (size exclusion-HPLC), CETP and lipoprotein lipase (LPL) activities and adiponectin. Additionally, in MetS + NAFLD type IV collagen 7S domain was measured. Results MetS + NAFLD showed increased VLDL-mass, VLDL particle number, VLDL-triglyceride% and large VLDL-% (p < 0.04). CETP activity tended to increase in MetS + NAFLD (p = 0.058), while LPL activity was unchanged. Moreover, in MetS + NAFLD, adiponectin was decreased (p < 0.001), and negatively correlated with VLDL-mass and VLDL particle number (p < 0.05), independently of insulin-resistance. Within MetS + NAFLD group, despite greater insulin-resistance, patients with severe fibrosis showed lower plasma triglycerides, VLDL-mass, VLDL-triglyceride%, large VLDL-% and CETP activity (p < 0.05), while type IV collagen was increased (p = 0.009) and inversely correlated with large VLDL-% (p = 0.045). Conclusions In MetS, NAFLD is associated with larger and triglyceride over-enriched circulating VLDLs, of greater atherogenicity. However, when NAFLD progresses to severe fibrosis, circulating VLDL features apparently improved, probably due to early alterations in hepatic synthetic function.
Fil: Lucero, Diego Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Fil: Miksztowicz, Verónica Julieta. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Fil: Gualano, Gisela. Hospital Nacional “Profesor Alejandro Posadas”; Argentina
Fil: Longo, Cristina. Hospital Nacional “Profesor Alejandro Posadas”; Argentina
Fil: Landeira, Graciela. Hospital Nacional “Profesor Alejandro Posadas”; Argentina
Fil: Álvarez, Estela. Hospital Nacional “Profesor Alejandro Posadas”; Argentina
Fil: Zago, Valeria. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Fil: Brites, Fernando Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Fil: Berg, Gabriela Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Fil: Fassio, Eduardo. Hospital Nacional “Profesor Alejandro Posadas”; Argentina
Fil: Schreier, Laura Ester. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina - Materia
-
Liver Fibrosis
Metabolic Syndrome
Nonalcoholic Fatty Liver Disease
Very Low-Density Lipoproteins - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/48624
Ver los metadatos del registro completo
id |
CONICETDig_e65d33b2eb4968013bc5aa4defc7dde8 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/48624 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteinsLucero, Diego MartínMiksztowicz, Verónica JulietaGualano, GiselaLongo, CristinaLandeira, GracielaÁlvarez, EstelaZago, ValeriaBrites, Fernando DanielBerg, Gabriela AliciaFassio, EduardoSchreier, Laura EsterLiver FibrosisMetabolic SyndromeNonalcoholic Fatty Liver DiseaseVery Low-Density Lipoproteinshttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Background We evaluated possible changes in VLDLcharacteristics, and metabolic related factors, in MetS-associated NAFLD and accompanying liver fibrosis. Methods We studied 36 MetS patients with biopsy-proven NAFLD (MetS + NAFLD) and 24 MetS without ultrasound NAFLD evidence. Further, MetS + NAFLD was sub-divided according to fibrosis stage into, non-to-moderate (F0–F2, n = 27) and severe (F3–F4, n = 9) fibrosis. We measured: lipid profile, VLDL composition and size (size exclusion-HPLC), CETP and lipoprotein lipase (LPL) activities and adiponectin. Additionally, in MetS + NAFLD type IV collagen 7S domain was measured. Results MetS + NAFLD showed increased VLDL-mass, VLDL particle number, VLDL-triglyceride% and large VLDL-% (p < 0.04). CETP activity tended to increase in MetS + NAFLD (p = 0.058), while LPL activity was unchanged. Moreover, in MetS + NAFLD, adiponectin was decreased (p < 0.001), and negatively correlated with VLDL-mass and VLDL particle number (p < 0.05), independently of insulin-resistance. Within MetS + NAFLD group, despite greater insulin-resistance, patients with severe fibrosis showed lower plasma triglycerides, VLDL-mass, VLDL-triglyceride%, large VLDL-% and CETP activity (p < 0.05), while type IV collagen was increased (p = 0.009) and inversely correlated with large VLDL-% (p = 0.045). Conclusions In MetS, NAFLD is associated with larger and triglyceride over-enriched circulating VLDLs, of greater atherogenicity. However, when NAFLD progresses to severe fibrosis, circulating VLDL features apparently improved, probably due to early alterations in hepatic synthetic function.Fil: Lucero, Diego Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; ArgentinaFil: Miksztowicz, Verónica Julieta. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; ArgentinaFil: Gualano, Gisela. Hospital Nacional “Profesor Alejandro Posadas”; ArgentinaFil: Longo, Cristina. Hospital Nacional “Profesor Alejandro Posadas”; ArgentinaFil: Landeira, Graciela. Hospital Nacional “Profesor Alejandro Posadas”; ArgentinaFil: Álvarez, Estela. Hospital Nacional “Profesor Alejandro Posadas”; ArgentinaFil: Zago, Valeria. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; ArgentinaFil: Brites, Fernando Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; ArgentinaFil: Berg, Gabriela Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; ArgentinaFil: Fassio, Eduardo. Hospital Nacional “Profesor Alejandro Posadas”; ArgentinaFil: Schreier, Laura Ester. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; ArgentinaElsevier Science2017-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/48624Lucero, Diego Martín; Miksztowicz, Verónica Julieta; Gualano, Gisela; Longo, Cristina; Landeira, Graciela; et al.; Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins; Elsevier Science; Clinica Chimica Acta; 473; 10-2017; 1-80009-8981CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.cca.2017.08.006info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0009898117302991info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:47:18Zoai:ri.conicet.gov.ar:11336/48624instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:47:18.555CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins |
title |
Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins |
spellingShingle |
Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins Lucero, Diego Martín Liver Fibrosis Metabolic Syndrome Nonalcoholic Fatty Liver Disease Very Low-Density Lipoproteins |
title_short |
Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins |
title_full |
Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins |
title_fullStr |
Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins |
title_full_unstemmed |
Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins |
title_sort |
Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins |
dc.creator.none.fl_str_mv |
Lucero, Diego Martín Miksztowicz, Verónica Julieta Gualano, Gisela Longo, Cristina Landeira, Graciela Álvarez, Estela Zago, Valeria Brites, Fernando Daniel Berg, Gabriela Alicia Fassio, Eduardo Schreier, Laura Ester |
author |
Lucero, Diego Martín |
author_facet |
Lucero, Diego Martín Miksztowicz, Verónica Julieta Gualano, Gisela Longo, Cristina Landeira, Graciela Álvarez, Estela Zago, Valeria Brites, Fernando Daniel Berg, Gabriela Alicia Fassio, Eduardo Schreier, Laura Ester |
author_role |
author |
author2 |
Miksztowicz, Verónica Julieta Gualano, Gisela Longo, Cristina Landeira, Graciela Álvarez, Estela Zago, Valeria Brites, Fernando Daniel Berg, Gabriela Alicia Fassio, Eduardo Schreier, Laura Ester |
author2_role |
author author author author author author author author author author |
dc.subject.none.fl_str_mv |
Liver Fibrosis Metabolic Syndrome Nonalcoholic Fatty Liver Disease Very Low-Density Lipoproteins |
topic |
Liver Fibrosis Metabolic Syndrome Nonalcoholic Fatty Liver Disease Very Low-Density Lipoproteins |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Background We evaluated possible changes in VLDLcharacteristics, and metabolic related factors, in MetS-associated NAFLD and accompanying liver fibrosis. Methods We studied 36 MetS patients with biopsy-proven NAFLD (MetS + NAFLD) and 24 MetS without ultrasound NAFLD evidence. Further, MetS + NAFLD was sub-divided according to fibrosis stage into, non-to-moderate (F0–F2, n = 27) and severe (F3–F4, n = 9) fibrosis. We measured: lipid profile, VLDL composition and size (size exclusion-HPLC), CETP and lipoprotein lipase (LPL) activities and adiponectin. Additionally, in MetS + NAFLD type IV collagen 7S domain was measured. Results MetS + NAFLD showed increased VLDL-mass, VLDL particle number, VLDL-triglyceride% and large VLDL-% (p < 0.04). CETP activity tended to increase in MetS + NAFLD (p = 0.058), while LPL activity was unchanged. Moreover, in MetS + NAFLD, adiponectin was decreased (p < 0.001), and negatively correlated with VLDL-mass and VLDL particle number (p < 0.05), independently of insulin-resistance. Within MetS + NAFLD group, despite greater insulin-resistance, patients with severe fibrosis showed lower plasma triglycerides, VLDL-mass, VLDL-triglyceride%, large VLDL-% and CETP activity (p < 0.05), while type IV collagen was increased (p = 0.009) and inversely correlated with large VLDL-% (p = 0.045). Conclusions In MetS, NAFLD is associated with larger and triglyceride over-enriched circulating VLDLs, of greater atherogenicity. However, when NAFLD progresses to severe fibrosis, circulating VLDL features apparently improved, probably due to early alterations in hepatic synthetic function. Fil: Lucero, Diego Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina Fil: Miksztowicz, Verónica Julieta. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina Fil: Gualano, Gisela. Hospital Nacional “Profesor Alejandro Posadas”; Argentina Fil: Longo, Cristina. Hospital Nacional “Profesor Alejandro Posadas”; Argentina Fil: Landeira, Graciela. Hospital Nacional “Profesor Alejandro Posadas”; Argentina Fil: Álvarez, Estela. Hospital Nacional “Profesor Alejandro Posadas”; Argentina Fil: Zago, Valeria. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina Fil: Brites, Fernando Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina Fil: Berg, Gabriela Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina Fil: Fassio, Eduardo. Hospital Nacional “Profesor Alejandro Posadas”; Argentina Fil: Schreier, Laura Ester. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina |
description |
Background We evaluated possible changes in VLDLcharacteristics, and metabolic related factors, in MetS-associated NAFLD and accompanying liver fibrosis. Methods We studied 36 MetS patients with biopsy-proven NAFLD (MetS + NAFLD) and 24 MetS without ultrasound NAFLD evidence. Further, MetS + NAFLD was sub-divided according to fibrosis stage into, non-to-moderate (F0–F2, n = 27) and severe (F3–F4, n = 9) fibrosis. We measured: lipid profile, VLDL composition and size (size exclusion-HPLC), CETP and lipoprotein lipase (LPL) activities and adiponectin. Additionally, in MetS + NAFLD type IV collagen 7S domain was measured. Results MetS + NAFLD showed increased VLDL-mass, VLDL particle number, VLDL-triglyceride% and large VLDL-% (p < 0.04). CETP activity tended to increase in MetS + NAFLD (p = 0.058), while LPL activity was unchanged. Moreover, in MetS + NAFLD, adiponectin was decreased (p < 0.001), and negatively correlated with VLDL-mass and VLDL particle number (p < 0.05), independently of insulin-resistance. Within MetS + NAFLD group, despite greater insulin-resistance, patients with severe fibrosis showed lower plasma triglycerides, VLDL-mass, VLDL-triglyceride%, large VLDL-% and CETP activity (p < 0.05), while type IV collagen was increased (p = 0.009) and inversely correlated with large VLDL-% (p = 0.045). Conclusions In MetS, NAFLD is associated with larger and triglyceride over-enriched circulating VLDLs, of greater atherogenicity. However, when NAFLD progresses to severe fibrosis, circulating VLDL features apparently improved, probably due to early alterations in hepatic synthetic function. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-10 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/48624 Lucero, Diego Martín; Miksztowicz, Verónica Julieta; Gualano, Gisela; Longo, Cristina; Landeira, Graciela; et al.; Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins; Elsevier Science; Clinica Chimica Acta; 473; 10-2017; 1-8 0009-8981 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/48624 |
identifier_str_mv |
Lucero, Diego Martín; Miksztowicz, Verónica Julieta; Gualano, Gisela; Longo, Cristina; Landeira, Graciela; et al.; Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins; Elsevier Science; Clinica Chimica Acta; 473; 10-2017; 1-8 0009-8981 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.cca.2017.08.006 info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0009898117302991 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier Science |
publisher.none.fl_str_mv |
Elsevier Science |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613474540322816 |
score |
13.070432 |